Development of a specific combination therapy for histone H3-mutant pediatric glioblastoma (A02)

• Subject Area: Hematology, Oncology
• Term: since 2019
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 404521405

In this project we will identify a histone H3 mutation- specific combination treatment strategy for H3.3-mutant glioblastoma, which will directly feed into a three-arm umbrella trial termed INFORM3-HGG. Patient-derived pedHGG tumor samples obtained through the INFORM registry will be screened to confirm the previously identified CDK9-BET axis but also to potentially detect further novel drug efficacies in addition to the CDK9-BET axis. Furthermore, we will test top candidates from our pedHGG cell line CRISPR screens in combination with radiation modalities.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1389: Understanding and Targeting Resistance in Glioblastoma (UNITE Glioblastoma)
• Applicant Institution: Ruprecht-Karls-Universität Heidelberg
• Project Heads: Dr. David Jones; Professor Dr. Olaf Witt